Tommaso Lorenzi

Tommaso Lorenzi

Auto-generated profile, based on publicly available information

Tommaso Lorenzi

Politecnico di Torino

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2015 in Cancer Research
Verified
Journal Article
Closed access
RCRebecca H. Chisholm
Rebecca H. Chisholm
TLTommaso Lorenzi
Tommaso Lorenzi
ALAlexander Lorz
Alexander Lorz
ALAnnette K. Larsen
Annette K. Larsen
LALuís Neves de Almeida
Luís Neves de Almeida
JCJean Clairambault
Jean Clairambault
In recent experiments on isogenetic cancer cell lines, it was observed that exposure to high doses of anticancer drugs can induce the emergence of a subpopulation of weakly proliferative and drug-tolerant cells, which display markers associated with stem cell–like cancer cells. After a period of time, some of the surviving cells were observed to change their phenotype to resume normal proliferation and eventually repopulate the sample. Furthermore, the drug-tolerant cells could be drug resensitized following drug washout. Here, we propose a theoretical mechanism for the transient emergence of such drug tolerance. In this framework, we formulate an individual-based model and an integro-differential equation model of reversible phenotypic evolution in a cell population exposed to cytotoxic drugs. The outcomes of both models suggest that nongenetic instability, stress-induced adaptation, selection, and the interplay between these mechanisms can push an actively proliferating cell population to transition into a weakly proliferative and drug-tolerant state. Hence, the cell population experiences much less stress in the presence of the drugs and, in the long run, reacquires a proliferative phenotype, due to phenotypic fluctuations and selection pressure. These mechanisms can also reverse epigenetic drug tolerance following drug washout. Our study highlights how the transient appearance of the weakly proliferative and drug-tolerant cells is related to the use of high-dose therapy. Furthermore, we show how stem-like characteristics can act to stabilize the transient, weakly proliferative, and drug-tolerant subpopulation for a longer time window. Finally, using our models as in silico laboratories, we propose new testable hypotheses that could help uncover general principles underlying the emergence of cancer drug tolerance. Cancer Res; 75(6); 930–9. ©2015 AACR.

11 January 2013 in ESAIM: Mathematical Modelling and Numerical Analysis
Verified
Journal Article
Open access
PDF file
ALAlexander Lorz
Alexander Lorz
TLTommaso Lorenzi
Tommaso Lorenzi
Michael HochbergMichael Hochberg
Michael Hochberg
JCJean Clairambault
Jean Clairambault
BPBenoît Perthame
Benoît Perthame
Resistance to chemotherapies, particularly to anticancer treatments, is an increasing medical concern. Among the many mechanisms at work in cancers, one of the most important is the selection of tumor cells expressing resistance genes or phenotypes. Motivated by the theory of mutation-selection in adaptive evolution, we propose a model based on a continuous variable that represents the expression level of a resistance gene (or genes, yielding a phenotype) influencing in healthy and tumor cells birth/death rates, effects of chemotherapies (both cytotoxic and cytostatic) and mutations. We extend previous work by demonstrating how qualitatively different actions of chemotherapeutic and cytostatic treatments may induce different levels of resistance. The mathematical interest of our study is in the formalism of constrained Hamilton–Jacobi equations in the framework of viscosity solutions. We derive the long-term temporal dynamics of the fittest traits in the regime of small mutations. In the context of adaptive cancer management, we also analyse whether an optimal drug level is better than the maximal tolerated dose.

6 December 2014 in Bulletin of Mathematical Biology
Verified
Journal Article
Closed access
PDF file
ALAlexander Lorz
Alexander Lorz
TLTommaso Lorenzi
Tommaso Lorenzi
JCJean Clairambault
Jean Clairambault
Alexandre EscargueilAlexandre Escargueil
Alexandre Escargueil
BPBenoît Perthame
Benoît Perthame

1 November 2016 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
RCRebecca H. Chisholm
Rebecca H. Chisholm
TLTommaso Lorenzi
Tommaso Lorenzi
JCJean Clairambault
Jean Clairambault

23 August 2016 in Biology Direct
Verified
Journal Article
Open access
PDF file
TLTommaso Lorenzi
Tommaso Lorenzi
RCRebecca H. Chisholm
Rebecca H. Chisholm
JCJean Clairambault
Jean Clairambault
A thorough understanding of the ecological and evolutionary mechanisms that drive the phenotypic evolution of neoplastic cells is a timely and key challenge for the cancer research community. In this respect, mathematical modelling can complement experimental cancer research by offering alternative means of understanding the results of in vitro and in vivo experiments, and by allowing for a quick and easy exploration of a variety of biological scenarios through in silico studies. To elucidate the roles of phenotypic plasticity and selection pressures in tumour relapse, we present here a phenotype-structured model of evolutionary dynamics in a cancer cell population which is exposed to the action of a cytotoxic drug. The analytical tractability of our model allows us to investigate how the phenotype distribution, the level of phenotypic heterogeneity, and the size of the cell population are shaped by the strength of natural selection, the rate of random epimutations, the intensity of the competition for limited resources between cells, and the drug dose in use. Our analytical results clarify the conditions for the successful adaptation of cancer cells faced with environmental changes. Furthermore, the results of our analyses demonstrate that the same cell population exposed to different concentrations of the same cytotoxic drug can take different evolutionary trajectories, which culminate in the selection of phenotypic variants characterised by different levels of drug tolerance. This suggests that the response of cancer cells to cytotoxic agents is more complex than a simple binary outcome, i.e., extinction of sensitive cells and selection of highly resistant cells. Also, our mathematical results formalise the idea that the use of cytotoxic agents at high doses can act as a double-edged sword by promoting the outgrowth of drug resistant cellular clones. Overall, our theoretical work offers a formal basis for the development of anti-cancer therapeutic protocols that go beyond the ‘maximum-tolerated-dose paradigm’, as they may be more effective than traditional protocols at keeping the size of cancer cell populations under control while avoiding the expansion of drug tolerant clones. This article was reviewed by Angela Pisco, Sébastien Benzekry and Heiko Enderling.

1 December 2015 in Journal of Theoretical Biology
Verified
Journal Article
Closed access
TLTommaso Lorenzi
Tommaso Lorenzi
RCRebecca H. Chisholm
Rebecca H. Chisholm
LDLaurent Desvillettes
Laurent Desvillettes
BHBarry D. Hughes
Barry D. Hughes